VPRIV® (velaglucerase alfa) for injection is a prescription medication indicated for long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.

Wayne’s story

AGE: 70s

Age at Diagnosis: 15

Location: Massachusetts, US

From unexplained childhood symptoms to navigating treatment options as an adult, Wayne’s story highlights the importance of perseverance and empowerment for those with type 1 Gaucher disease (GD1). Today, Wayne balances his condition with his active personal and professional life, as well as advocacy for the Gaucher disease community.

0:00

listen to Wayne’s story

Discover Wayne’s story below, or click play to hear
it in his own words.

Play Icon

A Childhood of Uncertainty

“I felt really out on my own. Like many people with type 1 Gaucher, I endured the fear and frustration of not knowing what was wrong with me year after year.”

From an early age, Wayne faced unexplained health challenges: frequent nosebleeds, persistent fatigue, easy bruising, and an enlarged spleen. At the time, little was known about GD1, leaving Wayne and his family feeling isolated and uncertain.

At ten years old, a sudden and severe pain in his right thigh led to hospitalization and speculation about serious conditions, including leukemia. After weeks of uncertainty, his symptoms improved, and he was diagnosed with osteomyelitis. However, similar painful episodes returned throughout his teenage years. Eventually, in high school, a hematologist diagnosed him with GD1.

With a name for his condition, Wayne and his family finally had a clearer path forward. They delved into learning more about the disease and its genetic origins. Discovering that GD1 was likely linked to their Ashkenazi Jewish heritage came as a shock, and caused Wayne’s parents some feelings of guilt. However, their growing knowledge also brought clarity, explaining many of Wayne’s past experiences and empowering his family to develop a proactive plan for monitoring and managing his symptoms.

Pushing Through Adversity

“During high school, I was walking with crutches full time, but I was managing okay. I put my efforts into things I could control. I made lots of friends and had a healthy curiosity about a lot of interests, especially science.”

Despite his diagnosis, treatment options were limited, and Wayne focused on moving forward with life. High school and college presented significant mobility challenges, forcing him to rely on crutches. However, he remained determined, pursuing his education and friendships while working toward a career in psychology.

watch Love, Me Video

Wayne Love, Me video

During graduate school, Wayne’s health took a serious turn when his spleen enlarged to a dangerous size, requiring an urgent splenectomy. During his recovery, a researcher requested to use his spleen for Gaucher disease research. This eye-opening moment inspired Wayne to contribute to the understanding of his condition and help others.

As Wayne built his career and family, medical advancements brought new hope. At a National Gaucher Foundation meeting, he learned about enzyme replacement therapy (ERT). Excited by the possibilities, he eagerly followed developments.

However, life threw another challenge his way. Wayne was diagnosed with aggressive soft tissue cancer in his leg. Determined to prioritize his family’s future, he made the difficult decision to undergo amputation to improve his chances of recovery. Through it all, Wayne remained committed to his role as a husband, father, and professional, leaning on his medical team and loved ones for support.

Wayne at his graduation

Discovering and Adapting to Treatment

“My treatment is just a part of my routine. No matter what life throws at me, I'm determined to keep up with my treatments.”

In 1993, Wayne began ERT at an infusion center. He and his doctor were pleased to see his symptoms improve. However, in 2009, an access issue led to a two-month gap in treatment. Although this may not happen to all patients coming off therapy, during this gap Wayne’s nosebleeds returned, and his liver function tests worsened. This experience prompted a switch to VPRIV after a discussion with his doctor.

On September 28, 2009, Wayne received his first infusion of VPRIV as part of a clinical trial. Before starting treatment, Wayne and his doctor discussed potential side effects in detail. With this knowledge, he was able to make an informed choice and was prepared to report any side effects that he found bothersome or did not go away.

Since he restarted treatment, his platelet and liver symptoms have stabilized, and he has not missed an infusion. Initially, he received infusions at an infusion center. Over time, he transitioned to home infusions, which take about two hours and have become a manageable part of his routine. With medications delivered to his home and a nurse assisting with the infusion process, Wayne enjoys greater flexibility in home infusions.

Embracing Every Moment

“My advice to new patients would be to relax and know that you can do this. Always be your own patient advocate and learn as much as you can. Take your disease into your own hands and stay determined to effect positive change. Our lives belong to us, not to a disease.”

Today, Wayne continues managing his GD1 with the support of his care team and VPRIV infusions. Home infusions have provided him with the flexibility to manage his treatment and life schedule, even during significant changes like moving from Connecticut to Florida and navigating the challenges of the COVID-19 pandemic. He works closely with his Takeda Patient Support Manager to help ensure treatment access and stays proactive in his healthcare management.

Beyond his medical journey, Wayne is deeply involved in the Gaucher disease community. He shares his story at conferences, connects with others through social media, and encourages patients to become informed and proactive in their care.

Wayne riding an ATV

Reflecting on his life, Wayne views his experiences as both challenging and rewarding. He has contributed to his community through disaster response work, supported his family, and found fulfillment in his career. Despite the obstacles posed by GD1, he remains firm in his belief that life is what you make of it. His message to others living with the condition is clear: take control, stay informed, and never lose sight of what truly matters.

important safety information <

Life-threatening hypersensitivity reactions, including anaphylaxis may occur with VPRIV treatment. This reaction may occur early in treatment or after many doses. Seek immediate help if you experience wheezing, shortness of breath, trouble breathing, itching, hives, rapid heartbeat, swelling of the tongue or throat.

important safety information <

Life-threatening hypersensitivity reactions, including anaphylaxis may occur with VPRIV treatment. This reaction may occur early in treatment or after many doses. Seek immediate help if you experience wheezing, shortness of breath, trouble breathing, itching, hives, rapid heartbeat, swelling of the tongue or throat. VPRIV should be administered under the supervision of a healthcare professional. Appropriate medical support should be available when VPRIV is administered.

Hypersensitivity reactions were the most commonly observed side effects in patients treated with VPRIV in clinical studies. The most commonly observed symptoms of hypersensitivity reactions were: headache, dizziness, low blood pressure, high blood pressure, nausea, tiredness/weakness, and fever. Hypersensitivity reactions in the clinical trials include any event considered related to and occurring within up to 24 hours of VPRIV infusion, including one case of anaphylaxis. Generally the reactions were mild and, in patients not previously treated, occurred mostly during the first 6 months of treatment and tended to occur less frequently with time. After the drug was approved, additional hypersensitivity reactions of chest discomfort, difficulty breathing, itching and vomiting have been reported. In some cases, vomiting can be serious and require hospitalization and/or stopping the medication.

If anaphylactic or other acute reactions occur, seek immediate medical care. Your healthcare provider will immediately discontinue the infusion of VPRIV and initiate the appropriate medical treatment. A hypersensitivity reaction should be treated based on the severity of the reaction. Your healthcare provider may manage a reaction by slowing the infusion rate or treating with medicine such as antihistamines, fever-reducing agents and/or corticosteroids or possibly stopping the medication and then restarting with a longer infusion time. For patients who have had symptoms of hypersensitivity reaction to enzyme replacement therapy, the doctor may consider treating the patient with antihistamines and/or corticosteroids before an infusion to help prevent such a reaction from happening.

The most commonly reported side effects during clinical studies (in ≥10% of patients) were hypersensitivity reactions, headache, dizziness, abdominal pain, nausea, back pain, joint pain, increased time it takes for blood to clot, tiredness/weakness, and fever. In clinical studies, the overall frequency of side effects was generally higher in the patients not previously treated with ERT than in the patients who switched from imiglucerase to VPRIV.

Talk to your doctor if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

The safety and efficacy profiles were similar in pediatric (ages 4 to 17) and adult patients. The safety of VPRIV has not been established in patients under 4 years of age. Side effects more commonly seen in pediatric patients compared to adult patients include (>10% difference): rash, increased time it takes for blood to clot, and fever.

The side effect profile in elderly patients was generally similar to that seen in pediatric and other adult patients. In general, dose selection for an elderly patient should be approached cautiously, considering other existing medical conditions.

As with all therapeutic proteins, there is a potential for developing antibodies to VPRIV. In clinical studies, 1 of 54 (2%) patients who had not previously been treated with ERT, who were then treated with VPRIV, developed antibodies. One additional patient developed antibodies to VPRIV during an extension study. It is unknown if having antibodies to VPRIV is associated with a higher risk of infusion reactions. Patients with an immune response to other enzyme replacement therapies who are switching to VPRIV should continue to be monitored for antibodies to VPRIV.

For additional safety information, please click here for Full Prescribing Information including WARNING for Risk of Anaphylaxis, and discuss with your doctor
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For more information, contact Takeda at 1-877-TAKEDA-7 (1-877-825-3327), or by email at medinfous@takeda.com